Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2008

View Archived Issues

Benzofuran analogues inhibit amyloid-beta aggregation

Preclinical studies demonstrate PSN-119-2's potential as an antidiabetic with anorectic effects

First-in-man study supports bevacizumab-eluting stent development

Alexza's Staccato loxapine phase III trial in schizophrenic patients meets primary endpoint

SAR-114646 prevents ventricular fibrillation without prolonging ventricular repolarization in dogs

YSPSL safe in phase I/II study in renal transplant patients

Duloxetine shows promise in premenstrual dysphoric disorder in preliminary study / News in Context

Pharmaleads reports on dual NEL/APN inhibitor for pain

Integral Molecular initiates NIAID sponsored R&D program in influenza inhibitors

New treatment options for neurological disorders disclosed in recent patents

Pfizer and Medivation sign global agreement to codevelop and market Dimebon

Neurologix licenses XIAP gene for treatment of HD from Aegera

Opexa and MRF sign research collaboration in MS to support development of Tovaxin

Optimer completes enrollment in second phase III prulifloxacin trial

Acucela and Otsuka enter agreement for ACU-4429 in dry AMD

FDA grants fast track designation to Neurotech's NT-501 for retinitis pigmentosa and dry AMD

Pharmaxis enrolls patients in second pivotal phase III cystic fibrosis trial

Ablynx and Merck Serono to codiscover and codevelop Nanobodies

Antisoma commences phase II trial of AS-1411 in renal cell carcinoma

Recent patents describe new antidiabetic agents

Cytotopia starts enrollment in phase II CYT-997 study in glioblastoma multiforme

Novel therapeutic agents for obesity reported in recent Taisho patent

ImClone submits sBLA for Erbitux in first-line head and neck cancer

Phase III aclidinium studies show statistical significance in patients with COPD

Teva and Barr receive FTC request for additional acquisition information

Zentiva's Board continues to advise shareholders to reject sanofi takeover offer

Celator receives FDA orphan drug designation for anticancer agent CPX-351

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...